These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23530389)

  • 41. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Epidemic process and vaccine prophylaxis of pertussis].
    Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):103-10. PubMed ID: 24000603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of mass Tdap vaccination to control an outbreak of pertussis in a high school--Cook County, Illinois, September 2006-January 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Jul; 57(29):796-9. PubMed ID: 18650787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection.
    Castagnini LA; Healy CM; Rench MA; Wootton SH; Munoz FM; Baker CJ
    Clin Infect Dis; 2012 Jan; 54(1):78-84. PubMed ID: 22075790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pertussis: current epidemiology and recommendations of the Health Council with regard to vaccination policy].
    van Wijngaarden JK; Huisman J; van der Meer JW; Visser HK
    Ned Tijdschr Geneeskd; 2000 Nov; 144(48):2297-301. PubMed ID: 11143295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Gothenburg pertussis vaccine study.
    Trollfors B; Taranger J
    Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
    [No Abstract]   [Full Text] [Related]  

  • 50. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
    Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
    Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Vaccine protection of Swedish children. Time for revision of replacing doses of diphtheria, tetanus, polio and pertussis].
    Olin P
    Lakartidningen; 2001 Aug; 98(35):3654-7. PubMed ID: 11577639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
    Beloradsky BH
    Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
    [No Abstract]   [Full Text] [Related]  

  • 54. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coughing up answers: a community's response to pertussis.
    Bass JB; Turpin-Saunders SR
    N C Med J; 2013; 74(5):420-4. PubMed ID: 24165773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Re-emergence of diphtheria and pertussis: implications for Nigeria.
    Sadoh AE; Oladokun RE
    Vaccine; 2012 Nov; 30(50):7221-8. PubMed ID: 23102975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arm your patients against whooping cough.
    Heavey E
    Nursing; 2008 Feb; 38(2):22-3. PubMed ID: 18223407
    [No Abstract]   [Full Text] [Related]  

  • 58. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acellular pertussis vaccines: the next step.
    Halperin SA
    Dev Biol Stand; 1997; 89():363-5. PubMed ID: 9272372
    [No Abstract]   [Full Text] [Related]  

  • 60. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.
    Heijbel H; Ciofi degli Atti M; Harzer E; Liese J; Preziosi MP; Rasmussen F; Schmitt HJ; Storsaeter J; Taranger J; Uberall M; Tozzi AE
    Dev Biol Stand; 1997; 89():101-3. PubMed ID: 9272338
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.